6732-85-0

Usage

Uses

Used in Pharmaceutical Industry:
1,3,5-Trihydroxyxanthone is used as a pharmaceutical compound for its potential therapeutic properties. The expression is: 1,3,5-Trihydroxyxanthone is used as a therapeutic agent for its potential benefits in treating various health conditions.
Used in Cosmetic Industry:
1,3,5-Trihydroxyxanthone is used as an active ingredient in the cosmetic industry for its potential skin-enhancing and protective properties. The expression is: 1,3,5-Trihydroxyxanthone is used as a cosmetic ingredient for its potential to improve skin health and provide protection against environmental stressors.
Used in Research and Development:
1,3,5-Trihydroxyxanthone is used as a research compound for further exploration of its chemical properties and potential applications in various fields. The expression is: 1,3,5-Trihydroxyxanthone is used as a research compound for the investigation of its properties and possible uses in different industries.
Note: The specific applications and reasons for using 1,3,5-Trihydroxyxanthone in each industry are not provided in the materials. The uses listed above are general and based on the potential properties of the compound.

InChI:InChI=1/C13H8O5/c14-6-4-9(16)11-10(5-6)18-13-7(12(11)17)2-1-3-8(13)15/h1-5,14-16H

Upstream product

• 6563-50-4 1,3,5-trimethoxy-9H-xanthen-9-one 
• 7169-06-4 2,3-dimethoxybenzoyl chloride 
• 108-95-2 phenol 
• 83-30-7 acide 2,4,6-trihydroxybenzoique 
• 120-80-9 benzene-1,2-diol 
• 108-73-6 3,5-dihydroxyphenol 
• 877-22-5 3-methoxysalicylic acid 
• 6343-00-6 2-hydroxy-2',3,4',6'-tetramethoxybenzophenone 
• 1521-38-6 2,3-dimethoxybenzoic acid 
• 6563-47-9 1,3-dihydroxy-5-methoxy-9H-xanthen-9-one 
• 303-38-8 2,3-Dihydroxybenzoic acid 

Downstream Products

• 20245-38-9 Rubraxanthone 
• 33390-41-9 8-deoxygartanin 
• 61243-70-7 C₂₇H₂₀O₅ 
• 26486-92-0 6-deoxyisojacareubin 
• 53377-61-0 1,3,5-trihydroxy-4-(3-methylbut-2-enyl)-9H-xanthen-9-one 

Relevant academic research and scientific papers

γ-Pyrone compounds as potential anti-cancer drugs

The γ-pyrones, artomunoxanthotrione epoxide, cyclocommunol, cyclomulberrin, and cyclocommunin exhibited potent inhibition of human PLC/PRF/5 and KB cells in-vitro. Dihydroisocycloartomunin showed significant and potent inhibition of human PLC/PRF/5 and KB

Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them

34 Xanthones were synthesized by microwave assisted technique. Their in?vitro inhibition activities against five cell lines growth were evaluated. The SAR has been thoroughly discussed. 7-Bromo-1,3-dihydroxy-9H-xanthen-9-one (3-1) was confirmed as the most active agent against MDA-MB-231?cell line growth with an IC50 of 0.46?±?0.03?μM. Combination of 3-1 and 5,6-dimethylxanthone-4-acetic acid (DMXAA) showed the best synergistic effect. Apoptosis analysis indicated different contributions of early/late apoptosis and necrosis to cell death for both monomers and the combination. Western Blot implied that the combination regulated p53/MDM2 to a better healthy state. Furthermore, 3-1 and DMXAA arrested more cells on G2/M phase; while the combination arrested more cells on S phase. All the evidences support that the 3-1/DMXAA combination is a better anti-cancer therapy.

An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization

Xanthones and their thio-derivatives are a class of pleiotropic compounds with various reported pharmacological and biological activities. Although these activities are mainly determined in laboratory conditions, the class itself has a great potential to be utilized as promising chemical scaffold for the synthesis of new drug candidates. One of the main obstacles in utilization of these compounds was related to the difficulties in their chemical synthesis. Most of the known methods require two steps, and are limited to specific reagents not applicable to a large number of starting materials. In this paper a new and improved method for chemical synthesis of xanthones is presented. By applying a new procedure, we have successfully obtained these compounds with the desired regioselectivity in a shorter reaction time (50 s) and with better yield (>80%). Finally, the preliminary in vitro screenings on different bacterial species and cytotoxicity assessment, as well as in silico activity evaluation were performed. The obtained results confirm potential pharmacological use of this class of molecules.

Synthesis, SAR and biological evaluation of natural and non-natural hydroxylated and prenylated xanthones as antitumor agents

In order to explore the detailed structure-activity relationship (SAR) around xanthone scaffold bearing hydroxyl and prenyl moieties, twenty-nine natural and non-natural hydroxylated and prenylated xanthones have been synthesized and evaluated for their in vitro anti-proliferative activities against five human cancer cell lines, including HepG2 (hepatocelluar carcinoma), HCT-116 (colon carcinoma), A549 (lung carcinoma), BGC823 (gastric carcinoma) and MDAMB- 231 (breast carcinoma). The SAR analysis revealed that the anti-proliferative activity of the xanthones is substantially influenced by the position and number of attached hydroxyl and prenyl groups, and the presence of hydroxyl group ortho to the carbonyl function of xanthone scaffold contributes significantly to their cytotoxicity. The new prenylated xanthone 20 with a relatively simple structure, namely 1,3,8-trihydroxy-2-prenylxanthone, was found to exhibit potent antitumor activities comparable to mangostin against all the five cancer cell lines. Further mechanistic studies suggested that compound 20 induces apoptosis and causes cell cycle arrest at S phase in HepG2 cells. These results have highlighted compound 20 as a new potential lead candidate for future development of novel potent broad-spectrum antitumor agents.

Identification of Xanthones as Selective Killers of Cancer Cells Overexpressing the ABC Transporter MRP1

Multidrug-resistance protein1 (MRP1) belongs to the ATP-binding cassette (ABC) transporter family. MRP1 mediates MDR (multidrug resistance) by causing drug efflux either by conjugation to glutathione (GSH) or by co-transport with free GSH (without covalen

PSOROSPERMIN AND ANALOGUES

Methods of making chiral psorospermin or its analogues and/or intermediates thereof are provided.

Synthesis of 2-hydroxy-3-methylbut-3-enyl substituted coumarins and xanthones as natural products. Application of the Schenck ene reaction of singlet oxygen with ortho-prenylphenol precursors

Application of our original photooxidation-reduction methodology to prenylated dihydroxycoumarin and trihydroxyxanthone compounds led to the corresponding ortho-(2-hydroxy-3-methylbut-3-enyl)phenol derivatives with yields ranging from 8 to 65%. In most of the reported experiments, the oxidation products distribution, after the photooxygenation step, was controlled by the competition between the large group effect and the stabilising phenolic assistance effect. We also showed that ortho-(3-hydroxy-3- methylbut-1-enyl)phenol derivatives could be considered as biogenetic precursors of 2,2-dimethylbenzopyranic structures.

Compounds for the treatment of hepatoma

Compounds of general Formula I in which the substituents of R1 -R7 are hydrogen, hydroxy group, C1-6 alkyl group, C1-6 alkoxy group, or epoxypropoxy, but at the most, six of the substituents can simultaneously be hydrogen, methoxy group, or hydroxy group, or epoxypropoxy group for activity against hepatoma. There are also described processes for the preparation of the novel compounds and useful intermediates. Substitute benzophenones are described.

Agent for inhibiting binding of 5-dihydro-testosterone with androgen receptor as well as process for obtaining same

An agent for inhibiting the binding of 5α-dihydrotestosterone with androgen receptor, which comprises at least one extract from herbs or one of specific xanthone compounds, and a process for obtaining the agent.